Scarica l'app Stockscreener
25.07
5.94%
1.405
Precedente Chiudi:
$23.67
Aprire:
$23.67
Volume 24 ore:
738.17K
Relative Volume:
0.35
Capitalizzazione di mercato:
$2.74B
Reddito:
$71.78M
Utile/perdita netta:
$-295.28M
Rapporto P/E:
-7.9359
EPS:
-3.1597
Flusso di cassa netto:
$-271.85M
1 W Prestazione:
+12.90%
1M Prestazione:
+0.99%
6M Prestazione:
+47.76%
1 anno Prestazione:
+142.27%
Intervallo 1D:
$23.61
$25.14
Intervallo di 1 settimana:
$21.23
$24.01
Portata 52W:
$9.14
$28.23
Nurix Therapeutics Inc Stock (NRIX) Company Profile
Nome
Nurix Therapeutics Inc
Settore
Industria
Telefono
(415) 660-5320
Indirizzo
1600 SIERRA POINT PKWY, BRISBANE
Compare NRIX vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
25.07 | 2.74B | 71.78M | -295.28M | -271.85M | -3.1597 |
VRTX
Vertex Pharmaceuticals Inc
|
509.45 | 129.13B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
239.78 | 95.73B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
807.22 | 83.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.39 | 53.54B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
370.76 | 41.94B | 5.76B | 514.49M | 1.10B | 4.4813 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-06-29 | Ripresa | Oppenheimer | Outperform |
| 2026-01-08 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-10-21 | Iniziato | Mizuho | Outperform |
| 2025-03-17 | Iniziato | Leerink Partners | Market Perform |
| 2024-12-10 | Iniziato | BTIG Research | Buy |
| 2024-12-06 | Iniziato | BMO Capital Markets | Outperform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-10-11 | Iniziato | Jefferies | Buy |
| 2024-09-06 | Ripresa | Robert W. Baird | Outperform |
| 2024-07-31 | Iniziato | Truist | Buy |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-03-09 | Iniziato | Barclays | Overweight |
| 2023-02-28 | Iniziato | Oppenheimer | Outperform |
| 2022-10-11 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-05-31 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-02-10 | Iniziato | Wells Fargo | Equal Weight |
| 2021-12-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-14 | Iniziato | SVB Leerink | Outperform |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-04-30 | Ripresa | Piper Sandler | Overweight |
| 2021-04-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-04-14 | Iniziato | Berenberg | Buy |
| 2020-11-19 | Iniziato | Robert W. Baird | Outperform |
| 2020-08-18 | Iniziato | JP Morgan | Overweight |
| 2020-08-18 | Iniziato | Needham | Buy |
| 2020-08-18 | Iniziato | Piper Sandler | Overweight |
| 2020-08-18 | Iniziato | Stifel | Buy |
Mostra tutto
Nurix Therapeutics Inc Borsa (NRIX) Ultime notizie
Form 4 Nurix Therapeutics Inc: Julia P. Gregory (Director) For: 14 October - Investing.com Canada
Nurix director Gregory sells $528,528 in stock following option exercise By Investing.com - Investing.com Canada
Nurix Therapeutics Director Sold Shares Worth Over $528K - TradingView
A director proposes selling 22,583 Nurix Therapeutics (Nasdaq: NRIX) shares acquired by exercising options. - Stock Titan
Form 4 Nurix Therapeutics Inc: Christine Ring (CLO) For: 2 October - Investing.com Canada
Nurix Therapeutics CLO sells $134k in stock after option exercise - Investing.com UK
Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass Estimates - Zacks Investment Research
The first patient has joined a trial testing two drugs for a type of blood cancer. - Stock Titan
Trade Figures, Fed in Picture This Week - baystreet.ca
An officer proposes selling 5,786 shares of Nurix Therapeutics (NRIX). - Stock Titan
Precigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock? - Zacks Investment Research
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock Has Consensus Price Target of $34.21 According to Analysts - MarketBeat
842,089 Shares in Nurix Therapeutics, Inc. $NRIX Bought by Bank of America Corp DE - MarketBeat
More than 5% of Nurix Therapeutics (NRIX) is reported by three parties, but one fund holds the shares. - Stock Titan
AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates - Zacks Investment Research
Nurix Therapeutics, Inc. (NRIX) Stock Analysis: A Biotech Gem With A 33% Upside Potential - DirectorsTalk Interviews
AMC Global Media Inc.Class A Common Stock (NQ: AMCX - The Chronicle-Journal
Behavioral Patterns of NRIX and Institutional Flows - Stock Traders Daily
We Think Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Drive Business Growth - Moomoo
Nurix Therapeutics, Inc. (NRIX) Latest Stock News & Headlines - Yahoo Finance
Here's Why You Should Add NRIX Stock to Your Portfolio Now - Yahoo Finance
Transcript : Nurix Therapeutics, Inc. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-08-2026 03 - marketscreener.com
Nurix Therapeutics (NRIX) Upgraded to Buy: Here's Why - Yahoo Finance
Nurix Therapeutics at Wells Fargo conference: pipeline, deal momentum By Investing.com - Investing.com India
Nurix Therapeutics at Wells Fargo conference: pipeline, deal momentum - investing.com
Legal & General Group Plc Buys Shares of 72,026 Nurix Therapeutics, Inc. $NRIX - MarketBeat
Nurix Therapeutics Stock Price Forecast. Should You Buy NRIX? - StockInvest.us
Wall Street Zen Downgrades Nurix Therapeutics (NASDAQ:NRIX) to Sell - MarketBeat
Bank of New York Mellon Corp Purchases New Shares in Nurix Therapeutics, Inc. $NRIX - MarketBeat
Nurix Therapeutics chief legal officer sells over $149k in shares By Investing.com - Investing.com South Africa
Braidwell LP Cuts Position in Nurix Therapeutics, Inc. $NRIX - MarketBeat
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Nurix Therapeutics chief legal officer sells over $149k in shares - Investing.com
Nurix Therapeutics chief legal officer sells over $149k in shares - Investing.com Australia
Nurix Therapeutics chief legal officer sells over $149k in shares - Investing.com India
Nurix Therapeutics chief legal officer sells over $149k in shares - Investing.com Nigeria
Nurix Therapeutics chief legal officer sells over $149k in shares - Investing.com UK
The Manufacturers Life Insurance Company Acquires New Holdings in Nurix Therapeutics, Inc. $NRIX - MarketBeat
Man Group plc Makes New $2.08 Million Investment in Nurix Therapeutics, Inc. $NRIX - MarketBeat
Alyeska Investment Group L.P. Takes $3.35 Million Position in Nurix Therapeutics, Inc. $NRIX - MarketBeat
Nurix CSO Gwenn Hansen sells $36,982 in stock - Investing.com
Nurix (NASDAQ: NRIX) insider files for new stock sale after recent plan trades - Stock Titan
Behavioral Patterns of NRIX and Institutional Flows - Stock Traders Daily
Nurix Therapeutics (NASDAQ:NRIX) Insider Gwenn Hansen Sells 1,452 Shares of Stock - MarketBeat
Nurix Therapeutics to Participate in Upcoming September Investor Conferences - Yahoo Finance
Elmind Capital LP Invests $11.16 Million in Nurix Therapeutics, Inc. $NRIX - MarketBeat
313,236 Shares in Nurix Therapeutics, Inc. $NRIX Acquired by ADAR1 Capital Management LLC - MarketBeat
58,898 Shares in Nurix Therapeutics, Inc. $NRIX Bought by Polymer Capital Management HK LTD - MarketBeat
Nurix (NRIX) Financial Update: EPS Comes in Below Forecast; Stock Move: The Stock Loses 2.40%Annual Earnings Summary - careplusvn.com
Nurix Therapeutics: Roche Has Changed The Economics Of The Bull Case (NASDAQ:NRIX) - Seeking Alpha
Nurix Therapeutics Inc Azioni (NRIX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Nurix Therapeutics Inc Azioni (NRIX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| GREGORY JULIA P | Director |
Oct 14 '26 |
Sale |
23.40 |
22,583 |
528,528 |
10,750 |
| GREGORY JULIA P | Director |
Oct 14 '26 |
Option Exercise |
1.86 |
22,583 |
42,004 |
33,333 |
| Ring Christine | Chief Legal Officer |
Oct 02 '26 |
Sale |
23.19 |
5,786 |
134,149 |
9,110 |
| Ring Christine | Chief Legal Officer |
Oct 02 '26 |
Option Exercise |
8.72 |
5,786 |
50,454 |
14,896 |
| CHRISTINE RING | Officer |
Oct 02 '26 |
Proposed Sale |
23.34 |
5,786 |
135,045 |
0 |
| Ring Christine | Chief Legal Officer |
Sep 02 '26 |
Sale |
25.76 |
5,787 |
149,072 |
9,110 |
| Ring Christine | Chief Legal Officer |
Sep 02 '26 |
Option Exercise |
8.72 |
5,787 |
50,463 |
14,897 |
| CHRISTINE RING | Officer |
Sep 02 '26 |
Proposed Sale |
26.04 |
5,787 |
150,693 |
0 |
| Hansen Gwenn | Chief Scientific Officer |
Sep 01 '26 |
Sale |
25.47 |
1,452 |
36,982 |
117,227 |
| Hansen Gwenn | Chief Scientific Officer |
Sep 01 '26 |
Option Exercise |
1.86 |
1,452 |
2,701 |
118,679 |
1.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):